Migraine treament with monoclonal antibodies
Migraine headaches affect around 6 to 8% of males and 10 to 12% of females. It is one of the top five neurological conditions and costs people healthy lives. There is little research on how the current preventative treatments for migraine work. Researchers have speculated that the suppression of cortical spreading depression could be a process at play. Typically migraine patients are given beta-blockers such as propranolol and metroprolol, anticonvulsants valproate and topiramate, and the calcium channel bocker flunarizine as first line medications. These drugs have been shown in randomized placebo controlled studies to reduce the frequency of migraine attacks. A new treatment option could be placed in monoclonal antibodies that target a neuropeptide called CGRP (Calcitonin Gene-related Peptide). CGRP plays is thought to play a key role in headaches. CGRP receptor antagonists have been developed for the treatment of acute … Read more